Table II.

The percentage of cells in different phases of the cell cycle following ATO treatment in SW900 cells.

	Cell cycle phase distribution, %
ATO dose	Sub-G1	G1	S	G2/M
0 µM	3.1±1.5	56.8±1.9	10.4±1.7	29.7±1.3
1.25 µM	2.3±0.9	47.3±5.6	11.4±0.5	39.0±5.9
2.5 µM	2.3±0.6	44.0±1.8a	11.6±0.2	42.1±2.6a
5 µM	1.9±0.3	40.8±5.6b	11.3±1.2	46.0±5.4b

^aP<0.01

^bP<0.001 compared with the control. ATO, arsenic trioxide.